Current status of tissue kallikrein inhibitors: Importance in cancer

Current Opinion in Investigational Drugs

Volumn 8, Issue 6, 2007, Pages 462-468

  Bhoola, Kanti D ^a   Misso, Neil L ^a   Naran, Anupam ^b   Thompson, Philip J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Cancer; Kallikrein; Kallistatin; Kinin; Protease inhibitor; Serpin

Indexed keywords

8 O [12 (LEUCINOYLAMINO)DODECANOYL] 8 O DEBUTANOYLTHAPSIGARIN; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; KALLIKREIN; KALLIKREIN INHIBITOR; KALLISTATIN; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN INHIBITOR; SERIN PROTEASE INHIBITOR KAZAL TYPE 5; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THAPSIGARGIN; TISSUE KALLIKREIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIBODY LABELING; BLOOD CLOTTING; CANCER; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; ENZYME ACTIVITY; FIBRINOLYSIS; GENE; GENE EXPRESSION; HUMAN; HYDROPHOBICITY; KALLIKREIN 1 GENE; KALLIKREIN 10 GENE; KALLIKREIN 11 GENE; KALLIKREIN 12 GENE; KALLIKREIN 13 GENE; KALLIKREIN 14 GENE; KALLIKREIN 15 GENE; KALLIKREIN 2 GENE; KALLIKREIN 3 GENE; KALLIKREIN 4 GENE; KALLIKREIN 5 GENE; KALLIKREIN 6 GENE; KALLIKREIN 7 GENE; KALLIKREIN 8 GENE; KALLIKREIN 9 GENE; KALLIKREIN GENE; MUTAGENESIS; NONHUMAN; PATHOGENESIS; PROSTATE CANCER; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; KALLIKREINS; MALE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASMS; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; TERMINOLOGY;

EID: 34249863596     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Frey EK, Kraut H, Werle E: Kallikrein (Padutin). Ferdinand Enke Verlag, Stuttgart, Germany (1950). •• This monograph was translated from German into English in 1977. The book provides a comprehensive review of the foundation of the kallikrein-kinin system.
2. Frey EK, Kraut H, Werle E, Vogel R, Zickgraf-Rüdel G, Trautschold I: Das Kallikrein-kinin-system und Seine Inhibitoren. Ferdinand Enke Verlag, Stuttgart, Germany (1968). • Soon after the discovery of tissue kallikrein a series of manuscripts were published in Biochemie Zeitschrift on the presence of kallikrein inhibitors in the circulation and organ tissues. This monograph collates this early research, from which inspiration has been drawn for the characterization of kallikrein inhibitors.
3. Ravindran S, Grys TE, Welch RA, Schapira M, Patston PA: Inhibition of plasma kallikrein by C1-inhibitor: Role of endothelial cells and the amino-terminal domain of C1-inhibitor. Thromb Haemost (2004) 92(6):1277-1283.
4. Bhoola K, Ramsaroop R, Plendl J, Cassim B, Dlamini Z, Naicker S: Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem (2001) 382(1):77-89. • This is one of the first publications to report the upregulation of hK1 in cancer, and delineate the carcinogenesis role of kinin peptides. The finding of hK1 expression during the formation of new capillaries by cultured microvascular endothelial cells is described.
5. Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinins: Kallikreins, kininogens and kininases. Pharmacol Rev (1992) 44(1):1-80. •• A critical review of the literature on kinins published from the early 1900s to 1992.
6. Bhoola KD, Fink E: Kallikrein-kinin cascade. In: Encyclopaedia of Respiratory Medicine. Laurent G, Shapiro SD (Eds), Elsevier Ltd, Oxford, UK (2006):483-493.
7. Chao J, Tillman DM, Wang MY, Margolius HS, Chao L: Identification of a new tissue-kallikrein-binding protein. Biochem J (1986) 239(2):325-331. •• A seminal article that reports the discovery of kallistatin. The biochemical properties of this serine protease inhibitor are described for the first time, which led to influential publications on the molecular mechanisms by which kallistatin interacts with hK1, resulting in the inhibition of hK1.
8. Luo LY, Jiang W: Inhibition profiles of human tissue kallikreins by serine protease inhibitors. Biol Chem (2006) 387(6):813-816.
9. Kreutzmann P, Schulz A, Standker L, Forssmann WG, Magert HJ: Recombinant production, purification and biochemical characterization of domain 6 of LEKTI: A temporary Kazal-type-related serine proteinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 803(1):75-81.
10. Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, Clayman GL, Jayakumar A: Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol Chem (2005) 386(11):1173-1184. •• This research paper describes the expression of hK5 and hK7 in the skin, and their inhibition by LEKTI. Mutations of LEKTI are considered to be implicated in the inherited skin disorder, the Netherton syndrome, typified by severe skin scaling.
11. Hekim C, Leinonen J, Narvanen A, Koistinen H, Zhu L, Koivunen E, Vaisanen V, Stenman UH: Novel peptide inhibitors of human kallikrein 2. J Biol Chem (2006) 281(18):12555-12560. •• This paper reports a novel concept that utilizes the enzymic activity of hK2 to deliver an anticancer drug.
12. Janssen S, Jakobsen CM, Rosen DM, Ricklis RM, Reineke U, Christensen SB, Lilja H, Denmeade SR: Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. Mol Cancer Ther (2004) 3(11):1439-1450. •• This paper describes the use of a combinatorial tetrapeptide library as an investigative tool for the identification of new peptide inhibitors. Prostate cancer cells secrete hK2, which can uniquely act as a target for proteolytic activation of cytotoxic drugs. This novel concept, if developed clinically, could have a major impact on cancer therapy, in particular in the treatment of prostate cancer.
13. Janssen S, Rosen DM, Ricklis RM, Dionne CA, Lilja H, Christensen SB, Isaacs JT, Denmeade SR: Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate (2006) 66(4):358-368. •• A cutting edge study on the development of a drug delivery system based on the concept described in reference [35].
14. Mahabeer R, Bhoola KD: Kallikrein and kinin receptor genes. Pharmacol Ther (2000) 88(1):77-89.
15. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV: The new human kallikrein gene family: Implications in carcinogenesis. Trends Endocrinol Metab (2000) 11(2):54-60.
16. Clements J, Hooper J, Dong Y, Harvey T: The expanded human kallikrein (KLK) gene family: Genomic organization, tissue-specific expression and potential functions. Biol Chem (2001) 382(1):5-14.
17. Yousef GM, Diamandis EP: The new human tissue kallikrein gene family: Structure, function and association to disease. Endocr Rev (2001) 22(2):184-204.
18. Borgono CA, Diamandis EP: The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer (2004) 4(11):876-890.
19. Obiezu CV, Diamandis EP: Human tissue kallikrein gene family: Applications in cancer. Cancer Lett (2005) 224(1):1-22.
20. Borgono CA, Michael IP, Diamandis EP: Human tissue kallikreins: Physiologic roles and applications in cancer. Mol Cancer Res (2004) 2(5):257-280.
21. Dlamini Z, Raidoo D, Bhoola K: Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma. Immunopharmacology (1999) 43(2-3):303-310.
22. 2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. J Clin Pathol (2005) 58(9):915-922.
23. Sawant S, Snyman C, Bhoola K: Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms. Int Immunopharmacol (2001) 1(12):2063-2080.
24. Moodley R, Snyman C, Odhav B, Bhoola KD: Visualization of transforming growth factor-β1, tissue kallikrein, and kinin and transforming growth factor-β receptors on human clear-cell renal carcinoma cells. Biol Chem (2005) 386(4):375-382.
25. Raidoo DM, Sawant S, Mahabeer R, Bhoola KD: Kinin receptors are expressed in human astrocytic tumour cells. Immunopharmacology (1999) 43(2-3):255-263.
26. Clements JA, Willemsen NM, Myers SA, Dong Y: The tissue kallikrein family of serine proteases: Functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci (2004) 41(3):265-312.
27. Dong Y, Kaushal A, Bui L, Chu S, Fuller PJ, Nicklin J, Samaratunga H, Clements JA: Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res (2001) 7(8):2363-2371.
28. Petraki CD, Papanastasiou PA, Karavana VN, Diamandis EP: Cellular distribution of human tissue kallikreins: Immunohistochemical localization. Biol Chem (2006) 387(6):653-663.
29. Roberts RA, Gullick WJ: Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene. J Cell Science (1989) 94(3):527-535.
30. Matsumura Y, Kimura M, Yamamoto T, Maeda H: Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res (1988) 79(12):1327-1334.
31. Plendl J, Snyman C, Naidoo S, Sawant S, Mahabeer R, Bhoola KD: Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol Chem (2000) 381(11):1103-1115.
32. Wolf WC, Evans MD, Chao L, Chao J: A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol (2001) 159(5):1797-1805.
33. Rehault S, Monget P, Mazerbourg S, Tremblay R, Gutman N, Gauthier F, Moreau T: Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem (2001) 268(10):2960-2968.
34. Tschesche H, Michaelis J, Kohnert U, Fedrowitz J, Oberhoff R: Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. Adv Exp Med Biol (1989) 247A:545-548.
35. Beaufort N, Debela M, Creutzburg S, Kellermann J, Bode W, Schmitt M, Pidard D, Magdolen V: Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol Chem (2006) 387(2):217-222.
36. Obiezu CV, Michael IP, Levesque MA, Diamandis EP: Human kallikrein 4: Enzymatic activity, inhibition, and degradation of extracellular matrix proteins. Biol Chem (2006) 387(6):749-759.
37. Zhou GX, Chao L, Chao J: Kallistatin: A novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem (1992) 267(36):25873-25880.
38. Chao J, Chao L: Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe Seyler (1995) 376(12):705-713.
39. Chen VC, Chao L, Chao J: A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. J Biol Chem (2000) 275(51):40371-40377. •• An outstanding paper describing experiments that delineated the molecular interactions between hK1 and kallistatin.
40. Chen VC, Chao L, Chao J: Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. J Biol Chem (2000) 275(49):38457-38466.
41. Chen VC, Chao L, Chao J: Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim Biophys Acta (2000) 1479(1-2):237-246.
42. 2 positions in design of inhibitors. Biochem J (2003) 371(3):1021-1025.
43. Pimenta DC, Melo RL, Caliendo G, Santagada V, Fiorino F, Severino B, de Nucci G, Juliano L, Juliano MA: Design of inhibitors for human tissue kallikrein using non-natural aromatic and basic amino acids. Biol Chem (2002) 383(5):853-857.
44. Debela M, Magdolen V, Schechter N, Valachova M, Lottspeich F, Craik CS, Choe Y, Bode W, Goettig P: Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem (2006) 281(35):25678-25688. •• An excellent paper that provides a rational basis for using specific molecular substrate features to design new inhibitors for tissue kallikreins.
45. Portaro FC, Cezari MH, Juliano MA, Juliano L, Walmsley AR, Prado ES: Design of kallidin-releasing tissue kallikrein inhibitors based on the specificities of the enzyme's binding subsites. Biochem J (1997) 323(1):167-171.
46. Houle S, Papez MD, Ferazzini M, Hollenberg MD, Vergnolle N: Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Br J Pharmacol (2005) 146(5):670-678.
47. Griesbacher T, Rainer I, Tiran B, Evans DM: Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats. Br J Pharmacol (2002) 137(5):692-700.
48. Szelke M, Evans DM, Jones DM, Fawcett L, Ashworth D, Olsson H, Featherstone RL, Church MK: Synthetic inhibitors of tissue kallikrein: Effects in vivo in a model of allergic inflammation. Braz J Med Biol Res (1994) 27(8):1943-1947.
49. Sousa MO, Miranda TL, Costa EB, Bittar ER, Santoro MM, Figueiredo AF: Linear competitive inhibition of human tissue kallikrein by 4-aminobenzamidine and benzamidine and linear mixed inhibition by 4-nitroaniline and aniline. Braz J Med Biol Res (2001) 34(1):35-44.